



Programme

Friday, 14 October 2022 – WORKSHOP

14:00-17:00	Emerging technologies for cancer profiling	Chair(s): Fabrice André, Villejuif, France
180'		
25'	Spatial genomics	Charles Antoine Dutertre, Villejuif, France
25'	Single cell sequencing	Celine Vallot, Paris, France
25'	Building personalized risk predictions from clinical	Elsa Bernard, New York, NY, USA
	cancer genomic profiling	
15'	Q&A	
30'	Coffee break	
25'	Artificial intelligence for image analyses	Jonas Teuwen, Amsterdam, Netherlands
25′	Integrating clinical, translational and basic sciences	Christos Sotiriou, Brussels, Belgium
10'	Q&A	

Saturday, 15 October 2022

08:25-08:30	Welcome from the Scientific Chairs	
5'		
5'	Welcome to the MAP Congress 2022	MAP 2022 Scientific Co-Chairs
08:30-10:00	Plenary session 1	Chair(s): Melissa Davis, New-York, NY USA
90'	Molecular characterisation in under-served	
	populations	
20'	Breast cancer in African American women	Melissa Davis, New-York, NY, USA
20'	Molecular characteristics of cancer in elderly	Kasit Chatsirisupachai, Liverpool, UK
	patients	
20'	Molecular characteristics of childhood cancer	Jacques Grill, Paris, France
20'	AML in ethnic minorities	Ann-Kathrin Eisfeld, Ohio, OH, USA
10'	Q&A	

10:00-10:30	Coffee break
60'	

10:30-12:00	Plenary session 2	Chair(s): Mariam Jamal-Hanjani, London, UK;
90'	Clonal evolution	Samra Turajlic, London, UK
25'	Tumour evolution and metastatic dissemination:	Mariam Jamal-Hanjani, London, UK
	Insights from the PEACE autopsy programme	
25'	Routes of metastatic spread	Kamila Naxerova, Boston, MA, USA (zoom
		joining)
25'	Evolution of treatment resistance in melanoma:	Samra Turajlic, London, UK
	Insights from the 100,000 genome project	
15'	Q&A	

12:00-13:00	Lunch & poster viewing
60'	





Saturday, 15 October 2022 cont.

12:15-13:00 45'	YO Vesalius talk Clinician-scientists: Finding the balance between clinic and research	
	Panelists	John Haanen, Amsterdam, Netherlands
		Yun Rose Li, San Francisco, CA, USA
		Samra Turajlic, London, UK
		Melissa Davis, New-York, NY,USA
		Mariam Jamal-Hanjani, London, UK
	YO Coordinator	Rille Pihlak, London, UK

13:05-13:50 45'	Molecular Tumour Board A case study of matching patient tumour genetic profiles to targeted therapies	Chair(s): Speaker(s)
10′	A case study of matching patient tumour genetic profiles to targeted therapies (part 1)	Antoine Italiano, Bordeaux, France
10′	A case study of matching patient tumour genetic profiles to targeted therapies (part 2)	David Tamborero, Barcelona, Spain
25'	Discussion and Q&A	All

13:55-14:25	Keynote lecture	Chair: John Haanen, Amsterdam, Netherlands
30'		
5'	Introduction to the keynote	John Haanen, Amsterdam, Netherlands
25′	Cancer immunotherapy with genome edited T cells	Chiara Bonini, Milan, Italy

14:30-16:00	Plenary session 3	Chair: Daniela Quail, Montreal, QC, Canada
90'	Tumour microenvironment	
25′	Myeloid cells and obesity in primary and metastatic cancer	Daniela Quail, Montreal, QC, Canada
25′	Immune cell contexture at the single cell level	Ankur Sharma, Perth, Australia
25′	Stroma heterogeneity in anti-cancer immunity	Helene Salmon, Paris, France
15'	Q&A	

16:00-16:30	Coffee break
30'	

16:30-18:00	Plenary session 4	Chair: Clare Slaney, Melbourne, Australia
90'	Immunotherapy	
25'	Signatures of neoantigen-reactive T cells from	Frank Lowery, Bethesda, MD, USA
	human metastatic cancers	
25'	Modulating genetics in CAR T cells	Clare Slaney, Melbourne, Australia
25′	HEVs and lymphocyte recruitment in tumours in response to immune checkpoint blockade	Jean-Philippe Girard, Toulouse, France
15'	Q&A	All



AMSTERDAM NETHERLANDS 14-16 OCTOBER 2022



Sunday, 16 October 2022

08:30-10:00	Plenary session 5	Chair: Francesca Demichelis, Trento, Italy
90'	Prostate cancers	
25′	Characterising metastatic migration patterns in prostate cancers using genomic alterations	Simone Zaccaria, London, UK
25′	Analysis of the epigenome in liquid biopsy for precision prostate cancer stratification	Francesca Demichelis, Trento, Italy
25′	Identification of therapeutic opportunities in prostate cancer through integrative ML approaches	Haitham A. Elmarakeby, Boston, MA, USA
15'	Q&A	

10:00-10:30	Coffee break
30'	

10:30-12:00	Plenary session 6	Chair: Leila Akkari, Amsterdam, Netherlands
90'	New resistance to cancer therapies	
25′	Understanding melanoma therapy resistance one cell at the time	Joanna Pozniak, Leuven, Belgium
25′	Therapy remodeling of the TME in brain tumors: Macrophages at play	Leila Akkari, Amsterdam, Netherlands
25′	Metabolism at the center stage of cancer drug resistance	Yi-Ru Yu, Lausanne, Switzerland
15'	Q&A	

12:00-13:00	Lunch
60'	

12:15-13:00	YO Mentorships	YO coordinator: Rille Pihlak, London, UK
45'		
Round table	Translational research: How to design and get the	Fabrice André, Villejuif, France
1	most out of these	
Round table	Bench to bedside: The "human" factors you need	Samra Turajlic, London, UK
2	to know about when designing clinical trials	
Round table	Real-life of a computational biologist: What it is	Simone Zaccaria, London, UK
3	about and how to do it	

13:05-13:35 30'	Keynote lecture Gordon Peters lecture	Chair: Charles Swanton, London, UK
5'	Introduction to the keynote lecture	Charles Swanton, London, UK
25′	Deciphering the highly complex antigen- presented landscape in cancer	Yardena Samuels, Rehovot, Israel





Sunday, 16 October 2022 cont.

13:40-15:10	Plenary session 7	Chair(s): Yun Rose Li, San Francisco, CA, USA
90'	Environmental impact on cancer	
25′	Genomic analysis of environmental impact on cancer risk	Andrea Degasperi, Cambridge, UK
25′	Human lifestyle factors, environment and cancer risk	Paul Brennan, Lyon, France
25′	The impact of carcinogens, obesity, and chronic inflammatory processes on mutational signatures and cancer risk in mouse tumour models	Yun Rose Li, San Francisco, CA, USA
15'	Q&A	

15:10-15:40	Coffee break
30'	

15:40-16:40 60'	Mini oral session	Chairs: Antonio Passaro, Milan, Italy and Samra Turajlic, London, UK
5′	Air Pollution Induced Non-Small Cell Lung Cancer: Towards Molecular Cancer Prevention	Emilia Lim, London, UK
5′	Tracking immunoediting from early to late stage lung cancer	Sonya Hessey, London, UK
5′	Genomic evolution of non-small cell lung cancer during the establishment and propagation of patient-derived xenograft models	Robert Hynds, London, UK
10'	Invited Discussant	Antonio Passaro, Milan, Italy
5'	Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer	Andrew Murtha, Vancouver, CA
5′	Hypomethylation of circulating retrotransposons: towards a non-invasive pan-cancer diagnosis	Charlotte Proudhon, Paris, France
5′	Pan-cancer characterization of Receptor Tyrosine Kinases alterations to sort targetable drivers from passengers.	Helene Vanacker, Lyon, France
5′	Measuring proliferation rates of distinct tumour clones using single-cell DNA sequencing	Olivia Lucas, London, UK
10'	Invited Discussant	Samra Turajlic, London, UK
5′	Q&A	